Profile data is unavailable for this security.
About the company
ProPhase Labs, Inc. is a biopharma, genomics, and diagnostics company. The Company provides whole genome sequencing solutions, while developing potential diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. Its segments include diagnostic services and consumer products. The diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third party payers and government organizations. The consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of over-the-counter consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services. Its CLIA labs and diagnostic technology provide wellness solutions.
- Revenue in USD (TTM)12.75m
- Net income in USD-27.76m
- Incorporated2015
- Employees113.00
- LocationProphase Labs Inc711 STEWART AVE, SUITE 200, GARDEN CITYNEW YORK 11530United StatesUSA
- Phone+1 (215) 345-0919
- Websitehttps://www.prophaselabs.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Xcelerate Inc | 3.96m | -296.19k | 9.90m | 1.00 | -- | 7.12 | -- | 2.50 | -0.0014 | -0.0014 | 0.0189 | 0.0032 | 1.51 | 6.13 | 3.90 | -- | -11.33 | 4.24 | -49.19 | -- | 71.71 | 74.10 | -7.48 | 1.93 | 0.4797 | -0.8218 | 0.7237 | -- | 6.63 | 10.43 | 17.00 | -- | 174.06 | -- |
| Pacific Health Care Organization Inc | 6.17m | 869.09k | 10.50m | 30.00 | 12.09 | 0.9214 | 11.59 | 1.70 | 0.0678 | 0.0678 | 0.4812 | 0.89 | 0.5259 | -- | 6.40 | 205,557.70 | 7.41 | 7.29 | 7.93 | 7.81 | 79.03 | 82.75 | 14.09 | 13.28 | -- | -- | 0.00 | -- | -2.00 | -3.70 | 55.80 | -10.80 | -15.93 | -- |
| Oncology Institute Inc | 378.93m | -57.46m | 11.70m | 800.00 | -- | 0.7565 | -- | 0.0309 | -0.7706 | -0.7706 | 5.08 | 0.2049 | 1.91 | 29.19 | 7.36 | 473,666.30 | -35.34 | -- | -44.12 | -- | 14.18 | 19.54 | -18.53 | -9.99 | 2.27 | -7.44 | 0.8553 | -- | 28.42 | 23.43 | -99,919.12 | -- | 45.68 | -- |
| Interpace Biosciences Inc | 44.89m | 4.89m | 11.80m | 108.00 | 2.43 | -- | 2.29 | 0.263 | 1.10 | 1.06 | 10.13 | -2.53 | 3.17 | 15.35 | 7.41 | 415,675.90 | 34.54 | -38.19 | -- | -69.73 | 60.46 | 49.44 | 10.88 | -41.01 | 0.5269 | 8.11 | -- | -- | 26.31 | 12.93 | 118.96 | -- | 0.9184 | -- |
| Aesthetic Medical Intl Hldg Grp Ltd(ADR) | 100.41m | -6.69m | 11.96m | 1.29k | -- | 3.11 | 6.04 | 0.1191 | -0.1485 | -0.1485 | 2.21 | 0.0806 | 1.29 | 20.82 | 77.36 | 78,081.45 | -9.06 | -23.36 | -35.45 | -48.58 | 45.39 | 55.32 | -7.02 | -23.72 | 0.2031 | -5.50 | 0.9581 | -- | 1.86 | -2.16 | 50.91 | -- | 3.70 | -- |
| Streamline Health Solutions Inc | 20.30m | -18.82m | 12.75m | 77.00 | -- | 12.03 | -- | 0.628 | -0.3277 | -0.3277 | 0.3499 | 0.2511 | 0.4397 | -- | 7.64 | 263,636.40 | -40.77 | -22.06 | -56.63 | -31.69 | 50.86 | 49.96 | -92.72 | -54.55 | -- | -4.46 | 0.4395 | -- | -9.21 | 0.2057 | -64.31 | -- | -11.72 | -- |
| Psychemedics Corp. | 20.26m | -3.00m | 13.79m | 116.00 | -- | 2.53 | -- | 0.6809 | -0.5142 | -0.5142 | 3.47 | 0.9238 | 1.69 | -- | 5.12 | 174,637.90 | -25.02 | -7.44 | -40.58 | -9.70 | 38.36 | 37.55 | -14.78 | -6.26 | -- | -292.90 | 0.0969 | -- | -12.45 | -12.33 | -283.21 | -- | -33.32 | -- |
| PharmChem Inc | 6.00m | 1.27m | 14.64m | 170.00 | 11.55 | 4.73 | 11.53 | 2.44 | 0.2727 | 0.2727 | 1.29 | 0.6661 | 1.67 | 7.23 | 8.04 | -- | 35.37 | -- | 44.59 | -- | 64.09 | -- | 21.17 | -- | 4.45 | -- | 0.00 | -- | 3.50 | -- | -16.95 | -- | -- | -- |
| ProPhase Labs Inc | 12.75m | -27.76m | 18.55m | 113.00 | -- | 0.3888 | -- | 1.45 | -1.50 | -1.50 | 0.6887 | 2.00 | 0.139 | 3.74 | 0.3629 | 112,858.40 | -30.25 | 0.9106 | -40.11 | 1.12 | -32.38 | 50.32 | -217.64 | 0.9325 | 1.33 | -12.78 | 0.2837 | 665.78 | -63.81 | 27.59 | -190.90 | -- | 86.46 | -- |
| Concord Medical Services Hldgs Ltd (ADR) | 65.18m | -52.36m | 19.32m | 727.00 | -- | -- | -- | 0.2964 | -11.99 | -11.99 | 14.92 | -68.07 | 0.0743 | 13.39 | 5.35 | 89,656.95 | -10.23 | -9.49 | -111.95 | -39.24 | -17.13 | -15.06 | -137.67 | -134.56 | 0.4556 | -1.89 | 0.6369 | -- | 13.84 | 23.00 | 39.21 | -- | -6.88 | -- |
| Elite Health Systems Inc | 0.00 | -1.18m | 21.73m | 2.00 | -- | 5.94 | -- | -- | -0.0938 | -0.0938 | 0.00 | 0.2106 | 0.00 | -- | -- | 0.00 | -45.56 | -14.62 | -49.63 | -19.89 | -- | -- | -- | -36.77 | -- | -- | 0.00 | -- | -- | -- | 38.97 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2024 | 651.89k | 3.42% |
| Renaissance Technologies LLCas of 30 Sep 2024 | 215.11k | 1.13% |
| Hightower Advisors LLCas of 30 Sep 2024 | 179.05k | 0.94% |
| Geode Capital Management LLCas of 30 Sep 2024 | 160.74k | 0.84% |
| Perritt Capital Management, Inc.as of 30 Sep 2024 | 82.93k | 0.44% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 66.14k | 0.35% |
| Chapin Davis, Inc. (Investment Management)as of 30 Sep 2024 | 50.00k | 0.26% |
| swisspartners AGas of 30 Jun 2024 | 50.00k | 0.26% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 44.66k | 0.23% |
| Newton Investment Management North America LLCas of 30 Sep 2024 | 35.80k | 0.19% |
